Çocuklarda Mikafungin Kullanımının Değerlendirilmesi
| Autor: | Edanur Yeşil, Nilgün Köksal, Beyhan Bülbül, Demet Timur, Salih Çağrı Çakır, Mustafa Hacimustafaoglu, Beyza Ener, Melike Sezgin Evim, Betül Sevinir, Hilal Özkan, Adalet Meral Güneş, Arife Özer, Duygu Düzcan Kilimci, Solmaz Celebi, Cansu Turan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Hepatoblastoma General Immunology and Microbiology Echinocandin business.industry Micafungin Neutropenia bacterial infections and mycoses medicine.disease Gastroenterology Hypokalemia Sepsis Infectious Diseases Intensive care Internal medicine Acute lymphocytic leukemia medicine medicine.symptom business medicine.drug |
| Zdroj: | Mikrobiyoloji Bulteni. 54:120-134 |
| ISSN: | 0374-9096 |
| Popis: | Micafungin is recommended especially in patients with liver and kidney failure and in the presence of other side effects due to antifungals apart from its known priority indications such as invasive candidiasis. The aim of this study was to evaluate the children who have received micafungin treatment. In the study, 125 children who were hospitalized in the pediatric wards and intensive care units of our hospital and had used micafungin between November 2016 and January 2019 were analyzed retrospectively. Clinical data, micafungin indication, blood values on the first and fourth days of the treatment, side effects of the drug and efficacy were evaluated. Sixty percent (75/125) of the patients were male and the mean age of all the patients were 58 ± 67 (0-215, 30) months. Approximately half of the cases (48%) had malignancy and 13% of them were premature. Sixty-two percent (n= 37) of the malignencies were hematological (27 acute lymphocytic leukemia, nine acute myeloid leukemia, one myelodysplastic syndrome) and 38% (n= 23) were oncological (six neuroblastoma, four Hodgkin lymphoma, two Non-Hodgkin's lymphoma, five sarcomas, one hepatoblastoma, five others) malignencies. The major cause of hospitalization was sepsis (53%). The patients had several risk factors like immunosuppressive therapy (n= 68, 54%), neutropenia (n= 61, 49%), central venous catheter (n= 102, 82%), nasogastric tube (n= 63, 50%), endotracheal intubation tube (n= 49, 39%), urinary catheter (n= 14, 11%) and total parenteral nutrition (n= 81, 65%). Thirteen percent (n= 16) of the cases were post-operative patients. Candida species were cultivated in 97 clinical specimens (blood, endotracheal aspirate, sputum, urine, etc.) among 23 (18%) of the patients. Thirteen (10%) of the patients had candidemia and 62% of them were non-albicans strains. In all candidemias, strains were echinocandin susceptible, and blood cultures were negative within four days. When all the patients (n= 125) were evaluated, a significant decrease in C-reactive protein, an increase in sodium, and a decrease in alanine aminotransferase were observed on the fourth day of micafungin treatment (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|